- Home
- CRBP vs SRZN Comparison
CRBP vs SRZN Comparison
Compare CRBP & SRZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRBP
- SRZN
- Stock Information
- Founded
- CRBP 2009
- SRZN 2015
- Country
- CRBP United States
- SRZN United States
- Employees
- CRBP N/A
- SRZN N/A
- Industry
- CRBP Biotechnology: Pharmaceutical Preparations
- SRZN Medicinal Chemicals and Botanical Products
- Sector
- CRBP Health Care
- SRZN Health Care
- Exchange
- CRBP Nasdaq
- SRZN Nasdaq
- Market Cap
- CRBP 73.4M
- SRZN 65.5M
- IPO Year
- CRBP N/A
- SRZN N/A
- Fundamental
- Price
- CRBP $7.34
- SRZN $8.13
- Analyst Decision
- CRBP Strong Buy
- SRZN Strong Buy
- Analyst Count
- CRBP 10
- SRZN 2
- Target Price
- CRBP $53.56
- SRZN $38.50
- AVG Volume (30 Days)
- CRBP 114.6K
- SRZN 12.6K
- Earning Date
- CRBP 05-06-2025
- SRZN 05-09-2025
- Dividend Yield
- CRBP N/A
- SRZN N/A
- EPS Growth
- CRBP N/A
- SRZN N/A
- EPS
- CRBP N/A
- SRZN N/A
- Revenue
- CRBP N/A
- SRZN $11,638,000.00
- Revenue This Year
- CRBP N/A
- SRZN N/A
- Revenue Next Year
- CRBP $150.00
- SRZN N/A
- P/E Ratio
- CRBP N/A
- SRZN N/A
- Revenue Growth
- CRBP N/A
- SRZN N/A
- 52 Week Low
- CRBP $4.64
- SRZN $5.90
- 52 Week High
- CRBP $61.90
- SRZN $18.17
- Technical
- Relative Strength Index (RSI)
- CRBP 52.51
- SRZN 46.15
- Support Level
- CRBP $7.05
- SRZN $7.60
- Resistance Level
- CRBP $7.62
- SRZN $8.70
- Average True Range (ATR)
- CRBP 0.49
- SRZN 0.84
- MACD
- CRBP -0.02
- SRZN 0.15
- Stochastic Oscillator
- CRBP 42.65
- SRZN 79.79
About CRBP Corbus Pharmaceuticals Holdings Inc.
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.
About SRZN Surrozen Inc.
Surrozen Inc is a clinical-stage biotechnology company committed to discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. Its product candidate includes SZN-1326 (Fzd5/Lrp6, SWAP), SZN-413 and SZN-043 (E3/ASGR1, SWEETS).